AtHeart Medical is moving on to the second phase of an IDE pivotal trial for its bioresorbable atrial septal defects occluder (ASD). The ASCENT ASD IDE trial is a 250- patient single-arm study that is ...

BAAR, Switzerland and MOUNTAIN VIEW, Calif -- atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...

BAAR, Switzerland and SANTA CLARA, Calif., Feb. 8, 2022 /PRNewswire/ -- atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal ...

Atheart Medical Inc. came on the market with splash, simultaneously announcing the company’s formation and its launch of a U.S. investigational device exemption (IDE) trial for the Resept ASD occluder ...

The FDA has given its final nod to W.L. Gore & Associates Inc. to market the Cardioform ASD occluder, aimed at correcting a congenital anomaly that causes a hole in the wall between the two upper ...

Transcatheter closure of atrial septal defects has become the standard of care for ostium secundum lesions, offering a minimally invasive alternative to open surgery. The procedure is performed under ...